Tirzepatide Reviews · v4.1 methodology · Updated October 15, 2026
Best Tirzepatide Telehealth Providers 2026
Released: · Last reviewed:
Independent editorial rankings of U.S. tirzepatide telehealth providers. NexLife is scored on our v4.1 methodology; other scores are from our May 2026 review (v3.0 rubric), with v4.1 re-scores pending. NexLife scores 94/100 on our v4.1 methodology, with compounded tirzepatide at $115/mo on a 12-month plan ($129 month to month), the same at every dose from 2.5 to 15 mg.
10 tirzepatide providers reviewedv4.1 methodologyAll 50 states + DC
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
The earlier v3.0 rubric (behind the May 2026 scores; v4.1 re-score pending)
Every tirzepatide telehealth provider on this page is scored against a fixed, publicly-published 100-point rubric structured as six transparency pillars. Read the full methodology.
Clinical protocol & physician of record (20 pts). Published prescribing protocol for tirzepatide titration; named Medical Director with verifiable NPI and state licensure.
Pharmacy traceability & CoA (20 pts). Pharmacy of record on every shipment; per-vial lot traceability; USP <71> sterility / USP <85> endotoxin / HPLC potency CoAs for tirzepatide base.
Real-world cohort outcomes & AE disclosure (20 pts). Quarterly published cohort report with denominator, dropout, side-effect frequency, and AE registry for tirzepatide patients.
All-inclusive flat pricing (15 pts). Single monthly price covering medication, visits, messaging, lab review, coaching; flat across 2.5→15 mg titration.
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. SURMOUNT-1 (NEJM 2022, PMID 35658024): 20.9% mean weight loss at 15 mg / 72 weeks in adults with obesity. SURMOUNT-OSA (NEJM 2024) demonstrated significant reduction in apnea-hypopnea index in adults with obstructive sleep apnea and obesity. Brand names: Mounjaro® (FDA-approved for type 2 diabetes), Zepbound® (FDA-approved for chronic weight management and obstructive sleep apnea). Read more →
Compounded vs brand-name tirzepatide
Compounded tirzepatide is usually dispensed by state-licensed 503A compounding pharmacies (USP <797> sterile compounding) and is not FDA-approved. In April 2026 FDA proposed not to add tirzepatide to the 503B bulks list; no final decision had been published as of October 15, 2026. It is not FDA-approved. FDA has warned about salt forms in compounded GLP-1 products; ask the pharmacy what form it uses. Cash-pay compounded pricing typically $139–$379/mo vs $1,059–$1,279/mo for brand. Compounded tirzepatide vs Zepbound comparison →
Editorial team
Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).
Frequently asked questions
Who ranks #1 for tirzepatide telehealth in 2026?
NexLife — 94/100 on our v4.1 methodology, $115/mo on a 12-month plan, the same at every dose from 2.5 to 15 mg.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound® (Eli Lilly).
Why does flat-rate pricing matter for tirzepatide?
Tirzepatide titrates from 2.5 mg to 15 mg over months. Many providers raise prices at each dose increase. Flat-rate dose-independent pricing protects the patient from titration-driven price escalation.
How does American Telehealth Review decide which provider ranks #1?
NexLife is scored on our v4.1 methodology (seven weighted categories, 100 points). Other providers’ scores come from our May 2026 review (v3.0 rubric); v4.1 re-scores are pending. Providers cannot pay to appear higher in organic comparisons.